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1278Objectives: In 2005, the time-based waiting list for lung transplantation was replaced by an illness/benefit lung
allocation score (LAS). Although short-term outcomes after transplantation have been reported to be similar be-
fore and after the new system, little is known about long-term results. The objective of this study was to evaluate
the impact of LAS on the development of bronchiolitis obliterans syndrome as well as on overall 3-year and
bronchiolitis obliterans syndrome–related survival.
Methods: Data obtained from the United Network for Organ Sharing were used to review 8091 patients who
underwent lung transplantation from 2002 to 2008. Patients were stratified according to time of transplantation
into those treated before initiation of the LAS (pre-LAS group, January 2002–April 2005, n ¼ 3729) and those
treated after implementation of the score (post-LAS group, May 2005–May 2008, n ¼ 4362). Overall, 3-year
survivals for patient groups were compared using a univariate analysis, Cox proportional hazards model to gen-
erate a relative risk, and Kaplan–Meier curve analyses.
Results:During the 3-year follow-up period, bronchiolitis obliterans syndrome developed in 22% of lung trans-
plant recipients (n¼ 1801). Although the incidence of postoperative bronchiolitis obliterans syndrome develop-
ment was similar between groups, post-LAS patients incurred fewer bronchiolitis obliterans syndrome–free days
(609 7.5 vs 682 9;P<.0001; log–rank testP¼ .0108) than did pre-LAS patients. Overall 3-year survival was
lower in post-LAS patients and approached statistical significance (P ¼ .05). Similarly, bronchiolitis obliterans
syndrome–related survival was worse for patients in the post-LAS group (log–rank test P ¼ .01).
Conclusions: In the current LAS era, lung transplant recipients have significantly fewer bronchiolitis obliterans
syndrome–free days after 3-year follow-up. Compared with the pre-LAS population, overall and bronchiolitis
obliterans syndrome–related survival appears worse in the post-LAS era. Limitation of known risk factors for
development of bronchiolitis obliterans syndrome–may prove even more important in this patient population.
(J Thorac Cardiovasc Surg 2011;141:1278-82)Although lung transplantation is a potentially life-saving
procedure and the treatment of choice for the majority of
end-stage lung diseases, long-term success rates are often
limited by chronic allograft rejection.1,2 Mortality after
lung transplantation remains the highest among all solid
organ recipients, with 5- and 10-year survivals of 53%
and 27%, respectively.3 Bronchiolitis obliterans syndrome
(BOS) is a clinical condition characterized by irreversible
airways obstruction, which accounts for approximately
30% of late mortality in lung transplant patients.4
Allocation of donor lungs for transplantation before 2005
was based on accumulated wait-list time without consider-
ation of medical urgency or survival expectation.5 In the
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The Journal of Thoracic and Cardiovascular Sur(UNOS) replaced the former systemwith a new lung alloca-
tion score (LAS) that considered wait-list urgency and post-
transplant survival in the prioritization of organ allocation.
The new system considers the 1-year survival of patients
without lung transplantation as well as the predicted
1-year survival after transplantation.5-7 Concerns have
arisen regarding its impact on short- and long-term out-
comes of transplant recipients inasmuch as the new system
prioritizes sicker patients to receive organs earlier. Accu-
mulated evidence has revealed comparable short-term out-
comes within the first year after transplantation.8,9
The objective of the current study was to evaluate the im-
pact of LAS on the development of chronic lung rejection
and BOS development. We hypothesized that BOS was
more likely to develop in patients in the post-LAS era and
that an increased incidence of BOS would result in higher
mortality in the post-LAS group.PATIENTS AND METHODS
Data Source
This study was reviewed by the University of Virginia Internal Review
Board and granted exemption from approval and consent. Data for all pa-
tients undergoing lung transplantation was obtained from the UNOSgery c May 2011
TABLE 1. Patients’ perioperative characteristics
Pre-LAS
(n ¼ 3729) (%)
Post-LAS
(n ¼ 4362) (%)
P
value*
Age (mean  SD) 49.1  14.7 51.3  14.9 .60
Gender (male) 1906 (51.1) 2504 (57.4) <.001
Creatinine 0.93 0.87 .002
Cerebrovascular disease 25 (0.7) 21 (0.9) .06
Peripheral vascular disease 40 (1.1) 25 (1.1) .97
History of cigarette use 335 (58.6) 2386 (60.9) .28
History of malignancy 121 (3.2) 250 (5.7) <.0001
Diagnosis <.0001
COPD 1384 (37.1) 1241 (28.5)
Pulmonary fibrosis 790 (21.2) 1293 (29.6)
Cystic fibrosis 598 (16.0) 621 (14.2)
Alpha-1 antitrypsin
deficiency
220 (5.9) 129 (3.0)
Pulmonary
hypertension
137 (3.7) 87 (2.0)
Bronchiectasis 78 (2.1) 75 (1.7)
Days on waiting
list (mean  SD)
436.2  455.8 263.4  448.7 <.0001
Transplant type
Single 1682 (45.2) 1616 (37.1) <.0001
Double 2043 (54.8) 2745 (62.9)
Ischemic time (h)
(mean  SD)
4.7  1.7 5.1  1.7 <.0001
SD, Standard deviation; COPD, chronic obstructive pulmonary disease. *Signifi-
cance P<.05.
Abbreviations and Acronyms
BOS ¼ bronchiolitis obliterans syndrome
COPD ¼ chronic obstructive pulmonary disease
ISHLT ¼ International Society of Heart and Lung
Transplantation
LAS ¼ lung allocation score
PGD ¼ primary graft dysfunction
UNOS ¼ United Network for Organ Sharing
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a prospectively collected database of every organ donation and transplan-
tation in the United States since 1987. Each transplant center collects and
reports data to UNOS based on data collection forms provided by UNOS.
All patient- and hospital-related identifiers are removed from published
data sets to provide de-identified data for analysis.
Study Design/Patient Characteristics
A total of 8091 patients were identified in the UNOS database as hav-
ing received lung transplants after January 2002. Patients admitted before
the date and/or undergoing simultaneous heart and lung transplantation
were excluded from the study. Lung transplant recipients were stratified
into 2 groups on the basis of operative era: pre-LAS patients (transplanta-
tion between January 2002 and May 2005) and post-LAS patients (trans-
plantation between May 2005 and May 2008). BOS was defined as
a declining forced expiratory volume in 1 second in the absence of another
cause according to International Society of Heart and Lung Transplanta-
tion (ISHLT) criteria.10 The incidence of postoperative BOS was defined
as the development of BOS (regardless of stage) within 3 years after
transplantation.
Variables Examined and Outcomes Measured
For all lung transplant recipients, patient demographics (eg, age, gender,
race), pulmonary risk factors (eg, diagnosis, oxygen requirements), comor-
bid disease, operative features (eg, transplant type, LAS score, ischemic
time), and postoperative outcomes (eg, dialysis, airway dehiscence, pulmo-
nary infection, acute rejection) were analyzed. Similarly, relevant donor
factors (eg, cytomegalovirus infection status, ABO status, infection status,
creatinine, cause of death) were considered. The primary end point of the
study was the time to BOS development for both pre- and post-LAS groups
up to 3 years after lung transplantation. Secondary end points were overall
3-year and BOS-related survival.
Statistical Analysis
Descriptive analysis comparing demographic data between the pre- and
post-LAS groups was performed using univariate analysis. Continuous var-
iables that were normally distributed were presented as a mean standard
error and compared using a 2-sample t test for independent samples. Con-
tinuous variables that were not normally distributedwere presented as ame-
dian and interquartile range with P value generated through a group
comparison using the Wilcoxon rank sum test. Categorical variables
were analyzed using a c2 or Fisher exact test. A comparison of time to
BOS development as well as survival time was performed by the Ka-
plan–Meier method and the log–rank test. The differences were quantified
using the Cox proportional hazards model via calculation of the hazard ra-
tio. Hazard ratios were reported as unadjusted and adjusted for age and di-
agnosis as per previous publications.11 All analyses were performed using
the SAS statistical software program (version 9.1.3 for Windows; SAS
Institute, Inc, Cary, NC).The Journal of Thoracic and CarRESULTS
A total of 3729 lung transplant recipients were identified
during the pre-LAS era, and 4362 recipients were identified
in the post-LAS era. BOS developed in 1801 (22%) of these
patients within 3 years, whereas BOS either did not develop
or else developed after 3 years in 6290 patients.
Perioperative characteristics for all lung transplant recip-
ients are presented in Table 1. There were differences in
gender, creatinine, history of malignancy, ischemic time,
and transplant type. As expected, there were significant dif-
ferences between the pre- and post-LAS groups on recipient
diagnosis as well. Whereas the pre-LAS group had a greater
number of patients with chronic obstructive pulmonary dis-
ease (COPD), the post-LAS group had a greater number of
patients with pulmonary fibrosis. There were also signifi-
cant differences observed in the type of transplants being
performed, single versus double, likely owing to a change
in transplantation protocols over those 2 time periods. The
2 groups were, however, similar with respect to age as
well as to the presence of preoperative cerebrovascular dis-
ease and peripheral vascular disease.
Lung transplant recipients in the post-LAS group in-
curred significantly more postoperative complications
(Table 2). In the post-LAS group, there was a higher inci-
dence of infection (40.9% vs 46.8%; P<.0001), as well
as a greater incidence of new-onset dialysis (5.2% vs
5.9%; P<.0001) after transplantation. Hospital length ofdiovascular Surgery c Volume 141, Number 5 1279
TABLE 2. Patients’ postoperative characteristics.
Pre-LAS
(n ¼ 3729) (%)
Post-LAS
(n ¼ 4362) (%)
P
value*
BOS at 3 y 799 (21.4) 1002 (23.0) .09
BOS-free days
(mean  SE)
682.6  9.0 609.9  7.5 <.0001
Mortality at 3 y
(mean  SE)
402.2  9.6 380.1  8.5 .08
Postoperative dialysis 193 (5.2) 256 (5.9) <.0001
Postoperative stroke 64 (1.7) 67 (1.5) <.0001
Postoperative infection 1526 (40.9) 1115 (46.8) <.0001
Length of stay (d)
(mean  SD)
23.6  0.5 24.9  0.5 .06
SE, Standard error; SD, standard deviation; BOS, bronchiolitis obliterans syndrome.
*Significance P<.05.
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LAS ¼ 23.6  0.5 days vs post-LAS ¼ 24.9  0.5 days;
P ¼ .06).
The incidence of BOS development at 3 years was similar
between patients in both pre- and post-LAS groups (21.4%
vs 23.0%; P ¼ .09). However, lung transplant recipients in
the post-LAS group tended to have BOS develop earlier
with significantly fewer BOS-free days compared with
those in the pre-LAS group (609.9 7.5 vs 682.6 9.0; un-
adjusted hazard ratio of 1.318; P<.0001). Importantly, the
hazard ratio did not change after adjusting for age and diag-
nosis, and Kaplan–Meier analysis demonstrated signifi-
cantly decreased BOS-free survival for patients in the
post-LAS group compared with pre-LAS patients
(Figure 1; log–rank P<.0001).
A trend toward lower overall 3-year survival was ob-
served among post-LAS patients and approached statistical
significance (log–rank P ¼ .05). Among the subset of lung
transplant recipients in whom BOS developed, similar mor-
tality rates were observed between the 2 groups (P ¼ .7).
However, patients in the post-LAS era demonstrated de-FIGURE 1. Kaplan–Meier curve of the development of the bronchiolitis
obliterans syndrome (BOS) demonstrates a significant decrease in BOS-
free days for patients in the post-LAS group compared to those in the
pre-LAS group (log–rank test P<.0001). LAS, Lung allocation score.
1280 The Journal of Thoracic and Cardiovascular Surcreased BOS-related survival compared with those in the
pre-LAS era (unadjusted hazard ratio ¼ 1.238; P ¼ .01;
Figure 2).DISCUSSION
In this study, the impact of LAS on the development of
BOS within 3 years after transplantation was evaluated.
Our results indicate that the number of lung transplantations
has increased in recent years after the implementation of this
new allocation score. Since the development of the LAS,
sicker patients with higher LASs have been reported to un-
dergo lung transplantation compared with those in the pre-
LAS era.9 Herein, we have also demonstrated that patients
in the post-LAS era have fewer BOS-free days compared
with those in the pre-LAS era. Despite these results, the
rate of development of BOS was not significantly different.
In addition, our analyses suggest a trend toward lower over-
all 3-year survival within post-LAS lung transplant patients.
Importantly, with respect to BOS-related survival, this trend
suggests that patients in the current, post-LAS era died sig-
nificantly earlier than did those in the pre-LAS era.
BOS continues to be a principal complication after lung
transplantation and the leading cause of death for those
who survive beyond the first year after the surgery.12 The
2009 ISHLT registry report revealed that among more
than 10,000 recipients who survived at least 14 days, BOS
developed in 28% by 2.5 years after transplantation and
in 74% by 10 years.13 In addition, the importance of timing
of BOS development has revealed that earlier development
of BOS after transplantation has been associated with
a worse functional and vital prognosis as well as graft fail-
ure.14 In our analysis, the 22% incidence of BOS at 3 years’
follow-up is in agreement with previously reported national
trends. However, the important finding of equivalent BOS
development rates among lung transplant recipients in the
pre- and post-LAS eras highlight the recent success ofFIGURE 2. Kaplan–Meier curve for 3-year bronchiolitis obliterans syn-
drome–related survival among patients in both pre- and post-LAS groups.
Among this cohort, survival was lower for patients in the post-LAS group
compared with the pre-LAS group (log–rank test P ¼ .01). LAS, Lung
allocation score.
gery c May 2011
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tion. The earlier development of BOS, as seen in the post-
LAS population in the current study, is equivalent to more
rapid deterioration of transplant-related morbidities. Fur-
thermore, BOS-related mortality is also accelerated, and
the life expectancy of such population is significantly
decreased.
Appropriate organ allocation for lung transplantation has
become critical considering current donor shortages. Begin-
ning in 1990, organ allocation for lung transplantation was
based on waiting time.6 However, in May 2005, the Organ
Procurement and Transplantation Network implemented
the new LAS system to allocate lungs to candidates based
on wait-list urgency and posttransplant survival. Wait-list
urgencywas defined as the expected number of days patients
live during the next year without transplantation, and post-
transplant survival was the expected number of days sur-
vived after transplantation.6 The main objectives of the
LAS were to decrease wait-list mortality, improve recipient
selection, and increase transplant benefits for recipients.
On the basis of available data, the LAS system appears to
have achieved its short-term goals. Since implementation of
the new system, there has been significant reduction in wait-
list time,9 and the new allocation system has significantly
decreased wait-list mortality.15 In fact, the annual death
rate for wait-list patients has decreased from 135 per 1000
patient-years at risk in 2004 to 128 in 2008.16 Moreover,
adoption of the LAS has improved recipient selection for
lung transplantation. Accumulating data, including that of
the present study, indicate that a shift in primary diagnostic
indication from COPD to idiopathic pulmonary fibrosis has
occurred since the introduction of the LAS system.7-9,17 The
data presented here are consistent with a report by Chen and
colleagues8 on the decreased rate of transplantation for pa-
tients with primary pulmonary hypertension despite higher
LAS. Although the reasons behind this are not entirely
clear, fewer patients with primary pulmonary hypertension
are listed and transplanted given the improvements in med-
ical treatment.
Improved lung transplant benefits in the post-LAS era
can be extrapolated from reported short- or long-term out-
comes. In a previous study, we reported on outcomes of
341 lung transplant patients from 5 US centers and docu-
mented that despite significantly higher intensive care unit
lengths of stay and prolonged ventilatory support in
post-LAS patients, total hospital stay, hospital mortality,
and 1-year survival were not adversely affected by the
new allocation system.9 Other series have further investi-
gated 1-year mortality rates of pre- and post-LAS recipi-
ents. McCue and associates18 reported a 1-year survival
advantage among post-LAS patients compared with the
pre-LAS patients. To the contrary, 2 larger studies failed
to show 1-year survival advantages for post-LAS pa-
tients.9,17 In another study, Chen and associates8 failed toThe Journal of Thoracic and Cardemonstrate any significant differences in 1-year mortality
with respect to transplant indication (cystic fibrosis, COPD,
idiopathic pulmonary arterial hypertension, and idiopathic
pulmonary fibrosis). There remains controversy; however,
2 recent studies have demonstrated that patients with higher
LAS had worse 30-day, 90-day, and 1-year survivals.11,19
In this study, we have extended the examination of out-
comes in the post-LAS era to investigate whether adoption
of the LAS has achieved its objectives to maximize benefits
to lung transplant recipients beyond the first year after trans-
plantation. To our knowledge, the current study is the first to
evaluate the impact of LAS on long-term outcomes. Con-
sidering that the reported median time to diagnosis of
BOS is 16 to 20 months after transplantation,20 we chose
to monitor all patients for 36 months to ensure sufficient
time for the development of signs and symptoms of BOS.
Consequently, the LAS system appears to have successfully
allocated organs to higher risk patients with no significant
change in the rate of chronic rejection. This finding dis-
proves our first hypothesis of worse long-term outcomes
in the post-LAS group. However, these patients are still at
higher risk for earlier development of BOS, which is shown
to result in earlier mortality and shorter life span after trans-
plantation. In addition to fewer BOS-free days, patients in
the post-LAS era had higher infection rates and signifi-
cantly more renal failure. One explanation for decreased
BOS-free days in post-LAS patients may be the increased
rate of primary graft dysfunction (PGD). The correlation
between PGD and BOS has been previously described in
a cohort of 334 adult lung transplant recipients.21 In this se-
ries, Daud and colleagues21 revealed that recipients who
had PGD have an increased risk of BOS that was indepen-
dent of acute rejection, lymphocytic bronchitis, and respira-
tory viral infections. In a separate study, Huang and
associates22 demonstrated the impact of PGD grade within
the first 3 days after transplantation on BOS development.
They demonstrated that PGD development was a significant
risk factor for BOS development and progression.
Both alloimmune-related (eg, acute cellular rejection, lym-
phocytic bronchitis, HLA mismatch) and nonalloimmune-
related risk factors (eg, PGD, gastroesophageal reflux
disease) have been implicated as potential risk factors for
the development of BOS.23We2 have recently reported donor
factors (donor age, current history of smoking, pulmonary
infection, donor hyperoxia) as important contributors to the
development of BOS.
Prolonged ischemic time has been reported as a potential
risk factor for the development of BOS. The results of
a large cohort of 752 patients suggest a close relationship
between graft ischemic time and long-term survival after
single and double lung transplantation, but not development
of BOS.24 In addition, Fiser and associates25 showed a trend
toward increased BOS with ischemic time of more than 6
hours, but this did not reach statistical significance.diovascular Surgery c Volume 141, Number 5 1281
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nificant increase in the onset, progression, and prognosis of
BOS in patients with longer ischemic times.26-28
The overall infection rate was higher in the post-LAS pa-
tients, which could potentially contribute to the development
ofBOS.Botha and colleagues29 have recently showna strong
association between allograft colonization with Pseudomo-
nas aeruginosa and the development of BOS within 2 years
of transplant. They have demonstrated shorter BOS-free
days in patients without any pretransplant bacterial reservoir
developing de novo allograft pseudomonal colonization as
compared with those remaining free of colonization.
There are several limitations of this study to note. The ret-
rospective study design introduces inherent selection bias. In
addition, the possibility for variations in reported data must
be considered as individual centers capture andmay interpret
patient data differently. In addition, UNOSdoes not allow for
the calculation of LAS for patients enrolled before 2005.
Thus, our ability to directly compare mean LAS in both
eras is constrained. Consequently, our belief that patients
in the pre-LAS group represent patient with lower scores is
based on our institutional lung transplantation database and
a recently reported multicenter investigation.9 UNOS also
does not provide data on the incidence of PGD, and this
may have an impact on the number of patients reported as
having developed BOS to the UNOS. Furthermore, the
UNOS database does not record stages of BOS, which limits
our ability to extrapolate advancing BOS stage as a correlate
to compromised long-term patient outcomes. Types of anti-
rejection regimens are not included in the UNOS database
and wewere not able to consider this variable in the compar-
ison between the 2 groups. Finally, the de-identified nature of
the UNOS database also constrained any efforts to further
scrutinize study groups to detect small clinical differences.
In conclusion, we have demonstrated that in the current
LAS era, lung transplant recipients have significantly fewer
BOS-free days after transplantation. Further, overall 3-year
and BOS-related survival appears lower among lung trans-
plant recipients since the adoption of the LAS system. Lim-
itation of known risk factors for BOS development may
help to improve posttransplant outcomes in this patient
population.References
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